Evidence map›Paper›PMID 41915859›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs-STAT3 Pathway.

Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Bo DaiDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-9827-3581
Shuo WangDepartment of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaotong PengDepartment of Gynecology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Kunpeng WuDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Mengyao WuDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Zhaoning LuObstetrics, and Gynecology Hospital, Fudan University, Shanghai, China.
Haoshu ZhongDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Xiaohan QianDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Shuiyi TanDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Hui YangDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Tanlezi SunObstetrics, and Gynecology Hospital, Fudan University, Shanghai, China.
Jing WangObstetrics, and Gynecology Hospital, Fudan University, Shanghai, China.
Jie ZhangObstetrics, and Gynecology Hospital, Fudan University, Shanghai, China.
Hua JiangObstetrics, and Gynecology Hospital, Fudan University, Shanghai, China.
Yin TongDepartment of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Tong ChenDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-7895-2077

Funding

National Key R&D Program of China 2022YFA1103500National Natural & Science Foundation of China 82100232National Natural & Science Foundation of China 82300260National Natural & Science Foundation of China 82330004Science and Technology Innovation Plan of Shanghai Science and Technology Commission 23Y21900300Shanghai Eastern Talent Program (2022)
6 · The paper itself

Abstract

Tumor-associated macrophage (TAM) is an important component of immunosuppressive microenvironment, which has been indicated as a key contributor in the relapse of diffuse large B-cell lymphoma (DLBCL). However, the molecular mechanism and the potential intervention regulating DLBCL-TAMs remains undefined. Here, we found that histone deacetylases (HDACs)-induced STAT3 deacetylation was critical for the M2 macrophages accumulation in DLBCL. Considering the unignorable adverse effects of HDAC inhibitor chidamide in DLBCL treatment, we developed a M2-targeted delivery system with peptide-modified extracellular vesicle (M2pep-EVs) to obtain optimized intra-tumour delivery of chidamide. In combined with pH-responsive hydrogel TSPBA/PVA, chidamide was loaded in M2pep-EVs, and was intelligently released as Chid@M2pep-EVs in situ in the acidic lymphoma microenvironment. By targeted delivery to M2 macrophages, chidamide sufficiently inhibited HDACs, enhanced STAT3 acetylation, reprogrammed M2 proportion into M1 phenotype, and ultimately suppressed lymphoma growth in vivo. With reduced dosage and adverse reactions, our Chid@M2pep-EVs system provides a new translational strategy for treating refractory/relapsed lymphoma.

Indexed as

AminopyridinesBenzamidesHistone Deacetylase InhibitorsHistone DeacetylasesLymphomaMacrophagesSTAT3 Transcription FactorTumor-Associated MacrophagesTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceSignal TransductionAminopyridinesBenzamidesHistone Deacetylase InhibitorsHistone DeacetylasesN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideSTAT3 protein, humanSTAT3 Transcription Factorchidamideengineered EVshydrogellymphomamacrophage reprogramming

Identifiers

PMID41915859
PMCPMC13325659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.